SCHEMBL10459409

SCHEMBL10459409

CC(=O)Nc1ccccc1NC(=S)C(C)C

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
HPGD P15428 2/20 0.53
TSHR P16473 3/20 0.53
MAPK1 P28482 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
HTT P42858 1/20 0.49
MAOA P21397 1/20 0.47
POLB P06746 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
EPHX1 P07099 1/20 0.45
GAA P10253 1/20 0.44
MDM4 O15151 1/20 0.44
TP53 P04637 1/20 0.44
LMNA P02545 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NAPRT Q6XQN6 1/20 0.44
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26246303 0.83 TSHR (0.59) ALDH1A1HPGDTSHRMAPK1SMN1; SMN2
SCHEMBL6689158 0.82 ALDH1A1 (0.74) ALDH1A1HPGDTSHRMAPK1SMN1; SMN2
SCHEMBL24259919 0.81 MDM4 (0.67) ALDH1A1HPGDTSHRMAPK1SMN1; SMN2
SCHEMBL10461228 0.80 ALDH1A1 (0.61) ALDH1A1HPGDTSHRMAPK1SMN1; SMN2
SCHEMBL3363637 0.79 ALDH1A1 (0.59) ALDH1A1HPGDTSHRMAPK1SMN1; SMN2
SCHEMBL14017837 0.77 ALDH1A1 (0.57) ALDH1A1HPGDTSHRMAPK1SMN1; SMN2
SCHEMBL2968579 0.76 ALDH1A1 (0.67) ALDH1A1HPGDTSHRMAPK1SMN1; SMN2
SCHEMBL5832230 0.76 KMT2A (0.58) ALDH1A1HPGDSMN1; SMN2KMT2AMEN1
SCHEMBL10463247 0.76 TSHR (0.59) ALDH1A1HPGDTSHRMAPK1SMN1; SMN2
SCHEMBL22299425 0.74 CYP2C19 (0.61) ALDH1A1HPGDTSHRMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022183081-A9 HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION AGILENT TECHNOLOGIES, INC. (US) 2023-09-21 WO disclosed
US-10597421-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2020-03-24 US disclosed
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. 2018-07-05 US disclosed
US-20120289691-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2012-11-15 US disclosed
US-20120184724-A1 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2012-07-19 US disclosed
WO-2010034024-A2 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2010-03-25 WO disclosed
US-20100076183-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289691-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS NSUN2, SNRPB2, RNGTT ALDH1A1 4103/4885HPGD 2011/4885TSHR 1669/4885
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS NSUN2, RNGTT, RNMT ALDH1A1 4361/4885HPGD 3084/4885TSHR 3650/4885
US-20100076183-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS RNGTT, RNMT, NSUN2 ALDH1A1 2890/4885HPGD 2415/4885TSHR 3050/4885
US-10597421-B2 Protected monomer and method of final deprotection for RNA synthesis NSUN2, RNGTT, RNMT ALDH1A1 4361/4885HPGD 3084/4885TSHR 3650/4885
US-20120184724-A1 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS RNMT, RNGTT, NSUN2 ALDH1A1 3173/4885HPGD 1649/4885TSHR 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.